DTNA

Across TCGA pan-cancer cohorts, DTNA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DTNA data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DTNA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DTNA expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where DTNA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	28	view →
GBM	DFS	Quartile	All	0.219	0.553	.009	12	view →
LSCC	DFS	Median	All	1.000	0.444	.002	8	view →
LUAD	DFS	Median	II,III,IV	0.772	0.888	.013	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DTNA–CCRCC (DFS)

Open the CCRCC breakdown →